Akebia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Akebia Therapeutics's estimated annual revenue is currently $235M per year.
- Akebia Therapeutics received $85.0M in venture funding in March 2018.
- Akebia Therapeutics's estimated revenue per employee is $436,803
- Akebia Therapeutics's total funding is $340.9M.
Employee Data
- Akebia Therapeutics has 538 Employees.
- Akebia Therapeutics grew their employee count by 8% last year.
Akebia Therapeutics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -94% | N/A | N/A |
#2 | $2.6M | 17 | N/A | N/A | N/A |
#3 | $6M | 39 | -20% | $176.5M | N/A |
#4 | $4.5M | 29 | N/A | N/A | N/A |
#5 | $2.6M | 17 | N/A | N/A | N/A |
#6 | N/A | 145 | -21% | $39.5M | N/A |
#7 | N/A | 0 | N/A | $9.5M | N/A |
#8 | $15.9M | 159 | -39% | $135M | N/A |
#9 | $1.7M | 11 | 57% | $20.9M | N/A |
#10 | $2.8M | 18 | 50% | $28.9M | N/A |
What Is Akebia Therapeutics?
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease. For more information, please visit our website at www.akebia.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$340.9M
Total Funding
538
Number of Employees
$235M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Akebia Therapeutics News
CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmace ...
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present at the Jefferies London Heal ...
CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and ...
On Tuesday, shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) marked $4.11 per share versus a previous $4.13 closing price. With having ...
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is among the top losers of the stock market today, sinking -3.89% or (-0.16 points) to $3.95 from its ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $101.3M | 540 | 4% | N/A |
#2 | $84.5M | 545 | 58% | N/A |
#3 | $86.8M | 560 | 47% | $775M |
#4 | $74.2M | 582 | 6% | N/A |
#5 | $131M | 582 | N/A | N/A |
Akebia Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-12-22 | $15.1M | A | Article | |
| 2009-07-29 | $16.0M | Undisclosed | Novartis Bioventures Ltd, Venture Investors LLC | Article |
| 2011-04-27 | $22.0M | Undisclosed | Novartis Venture Fund, Venture Investors LLC | Article |
| 2012-01-10 | $4.1M | Series B | Novartis Bioventures, Venture Investors | Article |
| 2013-06-05 | $41.0M | C | Satter Investment Management L | Article |
| 2015-04-24 | $64.6M | Undisclosed | UBS Investment Bank | Article |
| 2017-07-07 | $67.0M | Undisclosed | Morgan Stanley | Article |
| 2018-03-26 | $85.0M | Undisclosed | Morgan Stanley | Article |
